These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26172318)

  • 1. Subtle visuomotor difficulties in preclinical Alzheimer's disease.
    Mollica MA; Navarra J; Fernández-Prieto I; Olives J; Tort A; Valech N; Coll-Padrós N; Molinuevo JL; Rami L
    J Neuropsychol; 2017 Mar; 11(1):56-73. PubMed ID: 26172318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging.
    Valech N; Mollica MA; Olives J; Tort A; Fortea J; Lleo A; Belén SS; Molinuevo JL; Rami L
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S87-98. PubMed ID: 26445275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visuomotor impairment in early-stage Alzheimer's disease: changes in relative timing of eye and hand movements.
    Verheij S; Muilwijk D; Pel JJ; van der Cammen TJ; Mattace-Raso FU; van der Steen J
    J Alzheimers Dis; 2012; 30(1):131-43. PubMed ID: 22377783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.
    Fortea J; Sala-Llonch R; Bartrés-Faz D; Lladó A; Solé-Padullés C; Bosch B; Antonell A; Olives J; Sanchez-Valle R; Molinuevo JL; Rami L
    Biol Psychiatry; 2011 Jul; 70(2):183-90. PubMed ID: 21514924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity.
    Mollica MA; Tort-Merino A; Navarra J; Fernández-Prieto I; Valech N; Olives J; León M; Lleó A; Martínez-Lage P; Sánchez-Valle R; Molinuevo JL; Rami L
    Cortex; 2019 Dec; 121():117-124. PubMed ID: 31561128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
    Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
    J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion tensor imaging correlates of cognitive-motor decline in normal aging and increased Alzheimer's disease risk.
    Hawkins KM; Goyal AI; Sergio LE
    J Alzheimers Dis; 2015; 44(3):867-78. PubMed ID: 25374102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer's Disease: A Pilot Study.
    Patten RV; Fagan AM; Kaufman DAS
    Curr Alzheimer Res; 2018; 15(9):820-827. PubMed ID: 29623843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1.
    Tort-Merino A; Valech N; Peñaloza C; Grönholm-Nyman P; León M; Olives J; Estanga A; Ecay-Torres M; Fortea J; Martínez-Lage P; Molinuevo JL; Laine M; Rodríguez-Fornells A; Rami L
    J Alzheimers Dis; 2017; 58(3):855-870. PubMed ID: 28505969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EMIF-AD PreclinAD study: study design and baseline cohort overview.
    Konijnenberg E; Carter SF; Ten Kate M; den Braber A; Tomassen J; Amadi C; Wesselman L; Nguyen HT; van de Kreeke JA; Yaqub M; Demuru M; Mulder SD; Hillebrand A; Bouwman FH; Teunissen CE; Serné EH; Moll AC; Verbraak FD; Hinz R; Pendleton N; Lammertsma AA; van Berckel BNM; Barkhof F; Boomsma DI; Scheltens P; Herholz K; Visser PJ
    Alzheimers Res Ther; 2018 Aug; 10(1):75. PubMed ID: 30075734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.